Acute Lymphoblastic Leukemia in Children
Acute Lymphoblastic Leukemia in Children
复制标题
DOI：
10.5772/55655
复制
发表时间：
2013-05
影响因子：
0.3
通讯作者：
J. Roganović
中科院分区：
文献类型：
--
作者：
J. Roganović
儿童急性淋巴细胞白血病（ALL）治疗结果的非凡进展被列为肿瘤学史上最成功的故事之一，目前约有80%的儿童被治愈[1-5]。取得的进步主要是由于强化多药化疗的发展，确定可预测结局的临床和生物学变量及其在分层治疗中的应用，支持性治疗的重大进展，以及大规模、高度规范的多机构国家和国际临床试验的发展[6，7]。尽管取得了这一成功，但仍有改进的空间，包括为少数复发患者开发更好的治疗方法，开发毒性较小的治疗方法，并将注意力集中在抗白血病治疗可能引起的晚期效应的筛查和管理上[8，9]。
Extraordinary advances in the treatment outcome of childhood acute lymphoblastic leukemia (ALL) rank as one of the most successful stories in the history of oncology, with the current rate of approximately 80% of children being cured [1-5]. The improvements made have been mainly due to the development of intensive multiagent chemotherapy, identification of clinical and biologic variables predictive for outcome and their use in stratifying treatment, significant advances in supportive care, and development of large-scale, highly disciplined multiinstitutional national and international clinical trials [6,7]. In spite of this success, there remains place for improvement, including the development of better treatment for the minority of patients who relapse, the development of less toxic therapy, and focusing attention on screening and management of late effects that may potentially arise as a result of antileukemic treatment [8,9].